Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy
Author: Dai, Z.
Wang, Q.
Tang, J.
Wu, M.
Li, H.
Yang, Y.
Zhen, X.
Yu, C.
Citation: Biomaterials, 2022; 280:121261-1-121261-13
Publisher: Elsevier BV
Issue Date: 2022
ISSN: 0142-9612
Statement of
Zan Dai, Qiaoyun Wang, Jie Tang, Min Wu, Haoze Li, Yannan Yang, Xu Zhen, Chengzhong Yu
Abstract: Immunogenic cell death (ICD) is a promising strategy in cancer immunotherapy to induce high immunogenicity and activate the immune system. However, its efficacy is counteracted by the concurrent exposure of phos- phatidylserine (PS), an immunosuppressive signal on the surface of cancer cells. Here we report the synthesis of a bimetallic metal-organic framework (MOF) nanoparticle containing Gd3+ and Zn2+ (Gd-MOF-5) that can be used as an immunomodulator to downregulate the immunosuppressive PS signal and an ICD inducer to upregulate immunostimulatory signals. Gd3+ inhibits PS externalization via inhibiting the activity of scramblase, an enzyme to transfer PS to the outer leaflet of plasma membrane. Moreover, intracellular Zn2+ overload activates endo- plasmic reticulum stress for ICD induction. In combination with an immune checkpoint inhibitor (PD-L1 anti- body, denoted as aPDL1), Gd-MOF-5 activated potent immune response and effectively inhibited primary and distal tumor growth in a bilateral 4T1 tumor model. This work presents a new strategy using designed MOF materials to modulate the cell signalling and immunosuppressive microenvironment to improve the outcome of cancer immunotherapy.
Keywords: Metal-Organic Frameworks
Immunogenic Cell Death
Rights: © 2021 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.biomaterials.2021.121261
Grant ID: ARC
Appears in Collections:Chemical Engineering publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.